A Munc18-1 mutant mimicking phosphorylation by Down Syndrome-related kinase Dyrk1a supports normal synaptic transmission and promotes recovery after intense activity.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 02 2020
Historique:
received: 31 07 2019
accepted: 31 01 2020
entrez: 22 2 2020
pubmed: 23 2 2020
medline: 13 11 2020
Statut: epublish

Résumé

Phosphorylation of Munc18-1 (Stxbp1), a presynaptic organizer of synaptic vesicle fusion, is a powerful mechanism to regulate synaptic strength. Munc18-1 is a proposed substrate for the Down Syndrome-related kinase dual-specificity tyrosine phosphorylation-regulate kinase 1a (Dyrk1a) and mutations in both genes cause intellectual disability. However, the functional consequences of Dyrk1a-dependent phosphorylation of Munc18-1 for synapse function are unknown. Here, we show that the proposed Munc18-1 phosphorylation site, T479, is among the highly constrained phosphorylation sites in the coding regions of the gene and is also located within a larger constrained coding region. We confirm that Dyrk1a phosphorylates Munc18-1 at T479. Patch-clamp physiology in conditional null mutant hippocampal neurons expressing Cre and either wildtype, or mutants mimicking or preventing phosphorylation, revealed that synaptic transmission is similar among the three groups: frequency/amplitude of mEPSCs, evoked EPSCs, paired pulse plasticity, rundown kinetics upon intense activity and the readily releasable pool. However, synapses expressing the phosphomimic mutant responded to intense activity with more pronounced facilitation. These data indicate that Dyrk1a-dependent Munc18-1 phosphorylation has a minor impact on synaptic transmission, only after intense activity, and that the role of genetic variation in both genes in intellectual disability may be through different mechanisms.

Identifiants

pubmed: 32081899
doi: 10.1038/s41598-020-59757-y
pii: 10.1038/s41598-020-59757-y
pmc: PMC7035266
doi:

Substances chimiques

Munc18 Proteins 0
Stxbp1 protein, mouse 0
Threonine 2ZD004190S
Protein-Tyrosine Kinases EC 2.7.10.1
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3181

Références

Collins, M. O. et al. Proteomic analysis of in vivo phosphorylated synaptic proteins. J. Biol. Chem. 280, 5972–5982 (2005).
doi: 10.1074/jbc.M411220200
Huttlin, E. L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174–1189 (2010).
doi: 10.1016/j.cell.2010.12.001 pubmed: 3035969 pmcid: 3035969
Munton, R. P. et al. Qualitative and Quantitative Analyses of Protein Phosphorylation in Naive and Stimulated Mouse Synaptosomal Preparations. Mol. Cell. Proteomics 6, 283–293 (2007).
doi: 10.1074/mcp.M600046-MCP200
Tweedie-Cullen, R. Y., Reck, J. M. & Mansuy, I. M. Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J. Proteome Res. 8, 4966–4982 (2009).
doi: 10.1021/pr9003739
de Jong, A. P. & Verhage, M. Presynaptic signal transduction pathways that modulate synaptic transmission. Current Opinion in Neurobiology 19, 245–253 (2009).
doi: 10.1016/j.conb.2009.06.005
Verhage, M. et al. Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science (80-.). 287, 864–869 (2000).
doi: 10.1126/science.287.5454.864
Santos, T. C., Wierda, K., Broeke, J. H., Toonen, R. F. & Verhage, M. Early Golgi Abnormalities and Neurodegeneration upon Loss of Presynaptic Proteins Munc18-1, Syntaxin-1, or SNAP-25. J. Neurosci. 37, 4525–4539 (2017).
doi: 10.1523/JNEUROSCI.3352-16.2017 pubmed: 6596660 pmcid: 6596660
Courcet, J. B. et al. The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy. J. Med. Genet. 49, 731–736 (2012).
doi: 10.1136/jmedgenet-2012-101251
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).
doi: 10.1038/nature13772 pubmed: 4402723 pmcid: 4402723
Saitsu, H. et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat. Genet. 40, 782 (2008).
doi: 10.1038/ng.150
Stamberger, H. et al. STXBP1 encephalopathy A neurodevelopmental disorder including epilepsy. 1–10 (2016).
Kovačević, J. et al. Protein instability, haploinsufficiency, and cortical hyper-excitability underlie STXBP1 encephalopathy. Brain 141, 1350–1374 (2018).
doi: 10.1093/brain/awy046 pubmed: 5917748 pmcid: 5917748
Hornbeck, P. V. et al. PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).
doi: 10.1093/nar/gku1267
Barclay, J. W. et al. Phosphorylation of Munc18 by protein kinase C regulates the kinetics of exocytosis. J. Biol. Chem. 278, 10538–10545 (2003).
doi: 10.1074/jbc.M211114200
Genç, Ö., Kochubey, O., Toonen, R. F., Verhage, M. & Schneggenburger, R. Munc18-1 is a dynamically regulated PKC target during short-term enhancement of transmitter release. Elife 2014, 1–19 (2014).
Wierda, K. D. B., Toonen, R. F. G., de Wit, H., Brussaard, A. B. & Verhage, M. Interdependence of PKC-Dependent and PKC-Independent Pathways for Presynaptic Plasticity. Neuron 54, 275–290 (2007).
doi: 10.1016/j.neuron.2007.04.001
Meijer, M. et al. Tyrosine phosphorylation of Munc18‐1 inhibits synaptic transmission by preventing SNARE assembly. EMBO J. 37, e201796484 (2017).
Schmitz, S. K. et al. Presynaptic inhibition upon CB1 or mGlu2/3 receptor activation requires ERK/MAPK phosphorylation of Munc18‐1. EMBO J. 35, 1236–1250 (2016).
doi: 10.15252/embj.201592244 pubmed: 4888233 pmcid: 4888233
Park, J. H., Jung, M. S., Kim, Y. S., Song, W. J. & Chung, S. H. Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11α. J. Neurochem. 122, 1081–1091 (2012).
doi: 10.1111/j.1471-4159.2012.07861.x
Aranda, S., Laguna, A. & de la Luna, S. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J. 25, 449–462 (2011).
doi: 10.1096/fj.10-165837
Martí, E. et al. Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Res. 964, 250–263 (2003).
doi: 10.1016/S0006-8993(02)04069-6
Aranda, S., Alvarez, M., Turro, S., Laguna, A. & de la Luna, S. Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1A. Mol. Cell. Biol. 28, 5899–5911 (2008).
doi: 10.1128/MCB.00394-08 pubmed: 2547015 pmcid: 2547015
Wegiel, J. et al. Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res. 1010, 69–80 (2004).
doi: 10.1016/j.brainres.2004.03.008
Hämmerle, B. et al. Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation. Eur. J. Neurosci. 17, 2277–2286 (2003).
doi: 10.1046/j.1460-9568.2003.02665.x
Soppa, U. et al. The down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle 13, 2084–2100 (2014).
doi: 10.4161/cc.29104 pubmed: 4111700 pmcid: 4111700
Kurabayashi, N. & Sanada, K. Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells. Genes Dev. 27, 2708–2721 (2013).
doi: 10.1101/gad.226381.113 pubmed: 3877759 pmcid: 3877759
Guedj, F. et al. DYRK1A: A master regulatory protein controlling brain growth. Neurobiol. Dis. 46, 190–203 (2012).
doi: 10.1016/j.nbd.2012.01.007
Dang, T. et al. Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development. Mol. Psychiatry 23, 747–758 (2018).
doi: 10.1038/mp.2016.253
Martinez De Lagran, M. et al. Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. Cereb. Cortex 22, 2867–2877 (2012).
doi: 10.1093/cercor/bhr362
Wegiel, J., Gong, C. X. & Hwang, Y. W. The role of DYRK1A in neurodegenerative diseases. FEBS Journal 278, 236–245 (2011).
doi: 10.1111/j.1742-4658.2010.07955.x
Yamamoto, T. et al. Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6. Am. J. Med. Genet. Part A 155, 113–119 (2011).
doi: 10.1002/ajmg.a.33735
Dowjat, W. K. et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 413, 77–81 (2007).
doi: 10.1016/j.neulet.2006.11.026
Park, J., Song, W. J. & Chung, K. C. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci. 66, 3235–3240 (2009).
doi: 10.1007/s00018-009-0123-2
Raveau, M., Shimohata, A., Amano, K., Miyamoto, H. & Yamakawa, K. DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures. Neurobiol. Dis. 110, 180–191 (2018).
doi: 10.1016/j.nbd.2017.12.003
Fotaki, V. et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 22, 6636–47 (2002).
doi: 10.1128/MCB.22.18.6636-6647.2002 pubmed: 135639 pmcid: 135639
Kang, J. E., Choi, S. A., Park, J. B. & Chung, K. C. Regulation of the proapoptotic activity of Huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells. J. Neurosci. Res. 81, 62–72 (2005).
doi: 10.1002/jnr.20534
Ballif, B. A., Carey, G. R., Sunyaev, S. R. & Gygi, S. P. Large-Scale Identification and Evolution Indexing of Tyrosine Phosphorylation Sites from Murine Brain. J. Proteome Res. 7, 311–318 (2008).
doi: 10.1021/pr0701254
Havrilla, J. M., Pedersen, B. S., Layer, R. M. & Quinlan, A. R. A map of constrained coding regions in the human genome. Nat. Genet. 51, 88–95 (2019).
doi: 10.1038/s41588-018-0294-6 pubmed: 30531870 pmcid: 30531870
Sitz, J. H., Tigges, M., Baumgärtel, K., Khaspekov, L. G. & Lutz, B. Dyrk1A Potentiates Steroid Hormone-Induced Transcription via the Chromatin Remodeling Factor Arip4. Mol. Cell. Biol. 24, 5821–5834 (2004).
doi: 10.1128/MCB.24.13.5821-5834.2004 pubmed: 480880 pmcid: 480880
Guo, X., Williams, J. G., Schug, T. T. & Li, X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J. Biol. Chem. 285, 13223–13232 (2010).
doi: 10.1074/jbc.M110.102574 pubmed: 2857074 pmcid: 2857074
Toonen, R. F. G. et al. Munc18-1 expression levels control synapse recovery by regulating readily releasable pool size. Proc. Natl. Acad. Sci. 103, 18332–18337 (2006).
doi: 10.1073/pnas.0608507103
de Jong, A. P. H. et al. Phosphorylation of synaptotagmin-1 controls a post-priming step in PKC-dependent presynaptic plasticity. Proc. Natl. Acad. Sci. 113, 5095–5100 (2016).
doi: 10.1073/pnas.1522927113
Cijsouw, T. et al. Munc18-1 redistributes in nerve terminals in an activity- and PKC-dependent manner. J. Cell Biol. 204, 759–775 (2014).
doi: 10.1083/jcb.201308026 pubmed: 3941046 pmcid: 3941046
Misura, K. M., Scheller, R. H. & Weis, W. I. Three-dimensional structure of the neuronal-Sec. 1-syntaxin 1a complex. Nature 404, 355–362 (2000).
doi: 10.1038/35006120
Baker, R. W. et al. A direct role for the Sec. 1/Munc18-family protein Vps33 as a template for SNARE assembly. Science (80-.). 349, 1111–1114 (2015).
doi: 10.1126/science.aac7906
Cheung, G., Jupp, O. J. & Cousin, M. A. Activity-Dependent Bulk Endocytosis and Clathrin-Dependent Endocytosis Replenish Specific Synaptic Vesicle Pools in Central Nerve Terminals. J. Neurosci. 30, 8151–8161 (2010).
doi: 10.1523/JNEUROSCI.0293-10.2010 pubmed: 2889610 pmcid: 2889610
Kavalali, E. T. Multiple vesicle recycling pathways in central synapses and their impact on neurotransmission. J. Physiol. 585, 669–679 (2007).
doi: 10.1113/jphysiol.2007.137745 pubmed: 2375518 pmcid: 2375518
Kuromi, H. & Kidokoro, Y. Two synaptic vesicle pools, vesicle recruitment and replenishment of pools at the Drosophila neuromuscular junction. J. Neurocytol. 32, 551–565 (2003).
doi: 10.1023/B:NEUR.0000020610.13554.3c
Gulyas-Kovacs, A. et al. Munc18-1: Sequential Interactions with the Fusion Machinery Stimulate Vesicle Docking and Priming. J. Neurosci. 27, 8676–8686 (2007).
doi: 10.1523/JNEUROSCI.0658-07.2007 pubmed: 6672934 pmcid: 6672934
van Bon, B. W. M. et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol. Psychiatry 21, 126–132 (2016).
doi: 10.1038/mp.2015.5
Evers, J. M. G. et al. Structural analysis of pathogenic mutations in the DYRK1A gene in patients with developmental disorders. Hum. Mol. Genet. 26, 519–526 (2017).
pubmed: 28053047 pmcid: 5409128
Arbones, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M. & Delabar, J. M. DYRK1A and cognition: A lifelong relationship. Pharmacol. Ther. 194, 199–221 (2019).
doi: 10.1016/j.pharmthera.2018.09.010
Van Bon, B. W. M. et al. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. Clinical Genetics 79, 296–299 (2011).
doi: 10.1111/j.1399-0004.2010.01544.x
De Vries, K. J. et al. Dynamics of munc18-1 phosphorylation/dephosphorylation in rat brain nerve terminals. Eur. J. Neurosci. 12(1) 385–390 (2000).
Heeroma, J. H. et al. Trophic support delays but not prevent cell-intrinsic degeneration of neurons deficient for munc18-1. Eur. J. Neurosci. 20, 623–634 (2004).
doi: 10.1111/j.1460-9568.2004.03503.x
Naldini, L. et al. In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector. Science (80-.). 272, 263–267 (1996).
doi: 10.1126/science.272.5259.263
Vries, K. J. D., Geijtenbeek, A., Brian, E. C., Graan, P. N. E. D. & Ghijsen, W. E. J. M. Dynamics of munc18-1 phosphorylation/dephosphorylation in rat brain nerve terminals. Neuroscience 12, 385–390 (2000).
Schmitz, S. K. et al. Automated analysis of neuronal morphology, synapse number and synaptic recruitment. J. Neurosci. Methods 195, 185–193 (2011).
doi: 10.1016/j.jneumeth.2010.12.011

Auteurs

Jessica Classen (J)

Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University, 1081, HV, Amsterdam, The Netherlands.

Ingrid Saarloos (I)

Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University, 1081, HV, Amsterdam, The Netherlands.

Marieke Meijer (M)

Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University, 1081, HV, Amsterdam, The Netherlands.

Patrick F Sullivan (PF)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, PO Box 281, 171 77, Stockholm, Sweden.
Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Matthijs Verhage (M)

Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University, 1081, HV, Amsterdam, The Netherlands. matthijs@cncr.vu.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH